Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Hegde

Showing results (141-150 of 168) with videos related to

Pageof 17
Sort By:
Journal of Medicinal Chemistry|May 20, 2025
Discovery of an Orally Bioavailable and Brain Penetrant Selective Estrogen Receptor DegraderGuobao Zhang, Peter Q Huang, Kevin D Bunker, et al.
Radiation Protection Dosimetry|September 7, 2011
Distribution, enrichment and principal component analysis for possible sources of naturally occurring and anthropogenic radionuclides in the agricultural soil of Punjab state, IndiaAjay Kumar, Vikram M Joshi, Manish K Mishra, et al.
European Journal of Pharmacology|February 26, 2009
RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasiaKamna Nanda, Krishna S Naruganahalli, Suman Gupta, et al.
Cancer Research Communications|August 12, 2025
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid TumorsKenneth B DeSantes, Kimberly A McDowell, Paul M Sondel, et al.
Journal of Medicinal Chemistry|August 23, 2021
Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of CancerPeter Q Huang, Brant C Boren, Sayee G Hegde, et al.
Structure (London, England : 1993)|June 2, 2007
Structure and analysis of FCHo2 F-BAR domain: a dimerizing and membrane recruitment module that effects membrane curvatureWilliam Mike Henne, Helen M Kent, Marijn G J Ford, et al.
Heliyon|November 30, 2023
Enhanced O<sub>2</sub>/N<sub>2</sub> separation by QuaternizedMatrimid/Multiwalled carbon nanotube mixed-matrix membraneMallikarjunagouda Patil, Savitri G Hunasikai, Shridhar N Mathad, et al.
Endocrinology|May 12, 2011
The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociationXiao Hu, Sarah Du, Cansu Tunca, et al.
Journal of Cardiovascular Pharmacology|February 8, 2011
Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the ratLaxminarayan G Hegde, Cecile Yu, Travis Renner, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Discovery of TD-0212, an Orally Active Dual Pharmacology AT<sub>1</sub> Antagonist and Neprilysin Inhibitor (ARNI)R Murray McKinnell, Paul Fatheree, Seok-Ki Choi, et al.
Pageof 17

Showing results (141-150 of 168) with videos related to

Sort By:
Pageof 17
Journal of Medicinal Chemistry|May 20, 2025
Discovery of an Orally Bioavailable and Brain Penetrant Selective Estrogen Receptor DegraderGuobao Zhang, Peter Q Huang, Kevin D Bunker, et al.
Radiation Protection Dosimetry|September 7, 2011
Distribution, enrichment and principal component analysis for possible sources of naturally occurring and anthropogenic radionuclides in the agricultural soil of Punjab state, IndiaAjay Kumar, Vikram M Joshi, Manish K Mishra, et al.
European Journal of Pharmacology|February 26, 2009
RBx 6198: a novel alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasiaKamna Nanda, Krishna S Naruganahalli, Suman Gupta, et al.
Cancer Research Communications|August 12, 2025
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid TumorsKenneth B DeSantes, Kimberly A McDowell, Paul M Sondel, et al.
Journal of Medicinal Chemistry|August 23, 2021
Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of CancerPeter Q Huang, Brant C Boren, Sayee G Hegde, et al.
Structure (London, England : 1993)|June 2, 2007
Structure and analysis of FCHo2 F-BAR domain: a dimerizing and membrane recruitment module that effects membrane curvatureWilliam Mike Henne, Helen M Kent, Marijn G J Ford, et al.
Heliyon|November 30, 2023
Enhanced O<sub>2</sub>/N<sub>2</sub> separation by QuaternizedMatrimid/Multiwalled carbon nanotube mixed-matrix membraneMallikarjunagouda Patil, Savitri G Hunasikai, Shridhar N Mathad, et al.
Endocrinology|May 12, 2011
The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociationXiao Hu, Sarah Du, Cansu Tunca, et al.
Journal of Cardiovascular Pharmacology|February 8, 2011
Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the ratLaxminarayan G Hegde, Cecile Yu, Travis Renner, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Discovery of TD-0212, an Orally Active Dual Pharmacology AT<sub>1</sub> Antagonist and Neprilysin Inhibitor (ARNI)R Murray McKinnell, Paul Fatheree, Seok-Ki Choi, et al.
Pageof 17